Alcobra Ltd. (NASDAQ:ADHD) has received a consensus rating of “Hold” from the ten research firms that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $2.02.
A number of equities research analysts have recently issued reports on the company. Jefferies Group LLC restated a “hold” rating and issued a $1.25 price target on shares of Alcobra in a research report on Monday, June 12th. ValuEngine lowered Alcobra from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded Alcobra from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research report on Friday, June 2nd. Finally, Roth Capital set a $4.00 price target on Alcobra and gave the company a “buy” rating in a research report on Wednesday, May 31st.
Shares of Alcobra (NASDAQ ADHD) traded up 1.82% during trading on Tuesday, reaching $1.12. The company had a trading volume of 36,341 shares. The stock’s 50-day moving average price is $1.05 and its 200-day moving average price is $1.13. Alcobra has a 52 week low of $0.83 and a 52 week high of $4.93. The company’s market capitalization is $30.87 million.
Alcobra (NASDAQ:ADHD) last posted its quarterly earnings data on Friday, August 11th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. On average, equities analysts expect that Alcobra will post ($0.50) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/15/alcobra-ltd-adhd-receives-2-02-average-target-price-from-brokerages.html.
Hedge funds have recently modified their holdings of the business. Citadel Advisors LLC grew its holdings in shares of Alcobra by 7,251.0% during the first quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 101,514 shares during the last quarter. Worth Venture Partners LLC acquired a new stake in shares of Alcobra during the first quarter worth about $229,000. Finally, Royce & Associates LP boosted its stake in shares of Alcobra by 15.5% during the first quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock worth $849,000 after buying an additional 100,000 shares during the period. 29.68% of the stock is currently owned by institutional investors.
Alcobra Company Profile
Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.